Efficacy and safety results from ASCEMBL, a Phase III study of asciminib vs. bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update Meeting Abstract
| Authors: | Réa, D.; Hochhaus, A.; Mauro, M. J.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, W.; Apperley, J. F.; Cortes, J. E.; Abdo, A.; Fogliatto, L. M.; Kim, D. D. H.; le Coutre, P.; Saussele, S.; Annunziata, M.; Hughes, T. P.; Chaudhri, N.; Chee, L.; García-Gutiérrez, V.; Sasaki, K.; Kapoor, S.; Allepuz, A.; Quenet, S.; Bédoucha, V.; Boquimpani, C. |
| Abstract Title: | Efficacy and safety results from ASCEMBL, a Phase III study of asciminib vs. bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | cml; tki; phase iii; asciminib; trial-in-progress; ascembl |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S295 |
| End Page: | S296 |
| Language: | English |
| ACCESSION: | WOS:000897948100258 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01379-9 |
| Notes: | Meeting Abstract: CML-395 -- Source: Wos |
